Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs Ro

Maves
Graded #88

Lower grade

vs+8.400000000000006
Ro
Graded #38

Higher grade

The verdict

Ro takes it — 80.2/100 to 71.8/100.

Ro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A heavyweight platform with brand-name access — but opaque compounded pricing drags its score.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +16
84
68
Dose & formulationRo +21
65
86
Clinical oversightRo +10
76
86
Labs & monitoringRo +30
52
82
FulfillmentMaves +3
87
84
Contract termsRo +25
55
80
Maves · left barRo · right bar

The numbers

MetricMavesRo
WeighScore71.8/10080.2/100
GradeCB−
Scorecard rank#88#38
Semaglutide$99/mo (starting dose, first-month rate, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesMulti-state
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Maves

Graded #88 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
Ro

Graded #38 · B−

Strengths

  • Brand-name access + insurance support
  • Oral options
  • Well-funded platform

Where it loses points

  • Does not disclose compounded pricing up front
  • Premium positioning

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard